Goodman Richard E
Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, 143 Food Industry Complex, Lincoln, USA.
Food Chem Toxicol. 2008 Oct;46 Suppl 10:S24-34. doi: 10.1016/j.fct.2008.07.023. Epub 2008 Jul 31.
Proteins introduced into genetically modified (GM) organisms through genetic engineering must be evaluated for their potential to cause allergic disease under various national laws and regulations. The Codex Alimentarius Commission guidance document (2003) calls for testing of serum IgE binding to the introduced protein if the gene was from an allergenic source, or the sequence of the transferred protein has >35% identity in any segment of 80 or more amino acids to a known allergen or shares significant short amino acid identities. The Codex guidance recognized that the assessment will evolve based on new scientific knowledge. Arguably, the current criteria are too conservative as discussed in this paper and they do not provide practical guidance on serum testing. The goals of this paper are: (1) to summarize evidence supporting the level of identity that indicates potential risk of cross-reactivity for those with existing allergies; (2) to provide example bioinformatics results and discuss their interpretation using published examples of proteins expressed in transgenic crops; and (3) to discuss key factors of experimental design and methodology for serum IgE tests to minimize the rate of false negative and false positive identification of potential allergens and cross-reactive proteins.
根据各国法律法规,必须对通过基因工程导入转基因生物的蛋白质引发过敏性疾病的可能性进行评估。食品法典委员会指导文件(2003年)规定,如果导入的基因来自致敏源,或者转移蛋白的序列在任何80个或更多氨基酸片段中与已知过敏原的同源性超过35%,或者具有显著的短氨基酸同源性,则需要检测血清IgE与导入蛋白的结合情况。食品法典委员会的指导意见认识到,评估将根据新的科学知识不断发展。可以说,如本文所讨论的,目前的标准过于保守,而且它们没有为血清检测提供实际指导。本文的目标是:(1)总结支持表明现有过敏者存在交叉反应潜在风险的同源性水平的证据;(2)提供生物信息学结果示例,并使用转基因作物中表达的蛋白质的已发表示例讨论其解读;(3)讨论血清IgE检测实验设计和方法的关键因素,以尽量减少潜在过敏原和交叉反应蛋白的假阴性和假阳性识别率。